Semaglutide is a drug used to treat type 2 diabetes and belongs to GLP-1 receptor agonist. Semaglutide is a long-acting glucagon like peptide-1 (GLP-1) analog, which has potential therapeutic effect on type 2 diabetes (T2DM). It shares 94% homology with the human GLP-1 sequence and stimulates insulin secretion and reduces glucagon secretion by binding to GLP-1 receptors.

Semaglutide not only has hypoglycemic effects, but is also used for weight loss treatment. It can act on the digestive tract, causing delayed emptying and increasing satiety; In addition, it can suppress appetite by acting on the brain

>> Ordering semaglutide API & impurities online

>> Custom peptide synthesis | Fast delivery

What is GLP-1 receptor agonist?

These drugs mimic the action of GLP-1, promoting insulin secretion and inhibiting glucagon secretion. Common GLP-1 receptor agonists include liraglutide, beraglutide, lissinapine, dulaglutide, and semaglutide. Most peptides Omitzur are available in stock. Today, we will focus on introducing Semaglutide to everyone.

Background of Semaglutide R&D 

The development of semaglutide is based on research on GLP-1. GLP-1 is an endogenous peptide hormone secreted by the intestine after meals, which promotes insulin secretion, inhibits glucagon secretion, and increases satiety. However, the half-life of natural GLP-1 in the body is very short, which limits its application as a drug.

Therefore, researchers are committed to developing GLP-1 receptor agonists to simulate the action of GLP-1 and prolong its half-life. Semaglutide is developed by the Danish pharmaceutical company Novo Nordisk. The company has extensive research experience in the GLP-1 field and has previously successfully launched Liraglutide, another GLP-1 receptor agonist.

During the development of semaglutide, researchers extended its half-life through chemical modification, allowing it to be injected once a week. This greatly improves patients' compliance and quality of life. The clinical trial phase includes multiple large, multicenter, randomized, double-blind, placebo-controlled studies. These experiments show that semaglutide is superior to many existing treatment options in reducing blood sugar and weight.

In 2017, Semaglutide was first approved by FDA in the United States for the treatment of type 2 diabetes, with the trade name Ozempic. In 2021, the FDA approved semaglutide for the treatment of obesity under the trade name Wegovy. Semaglutide has been widely accepted and used worldwide, especially in patients with diabetes and obesity.

The success of Ozempic and Wegovy in the market has also driven the popularity of drugs such as GLP-1 receptor agonists, inspiring more companies to enter this field. In addition to Novo Nordisk's Semaglutide , other companies are also developing and promoting similar GLP-1 receptor agonists, such as Eli Lilly's Dulaglutide and Sanofi's Lysine. New GLP-1 receptor agonists and combination therapies are constantly entering the market, which also promotes rapid development and innovation in this field.

Note: This product is for scientific research and laboratory use only, not for personal sale, and cannot be consumed directly. The potential efficacy and applications mentioned in the product introduction are from publicly published literature and are for reference only, not for actual use. 

 Order Peptide Now:

 1. Click to send inqauiry online:  Make Inquiry Now 

 2. Send mail to us: [email protected]

  * Please mail us product name and quantity needed, Omizzur will get back to you within 1 hour.